Bio Essence Corporation Reports 137% Revenue Increase and Reduced Net Losses for Nine Months Ending September 30, 2025

Bio Essence Corporation reported its financial results for the nine months ending September 30, 2025, revealing a significant increase in revenue and a notable reduction in net losses compared to the same period in the previous year. The company generated total revenues of $418,112, a 137% increase from $176,385 in the prior year. This growth was primarily driven by a substantial rise in manufacture service revenue, which reached $416,896, compared to $136,109 in the previous year. The company did not report any sales of goods during this period, contrasting with $37,415 in the same period last year.

Despite the increase in revenue, Bio Essence reported a net loss of $132,890 from continuing operations, a significant improvement from the loss of $1,538,158 reported for the same period in 2024. The reduction in losses was attributed to a combination of higher revenues and decreased operating expenses, which fell to $414,608 from $573,469 in the previous year. The company’s gross profit also increased to $284,992, up from $110,179, reflecting a gross profit margin of 68.16% compared to 62.47% in the prior year.

In terms of operational developments, Bio Essence has undergone strategic changes, including the dissolution of its subsidiaries, Bio Essence Pharmaceutical Inc. and Bio Essence Herbal Essentials, Inc., and the outsourcing of its manufacturing services following the sale of its manufacturing subsidiary, BEP, in December 2023. The company is now focusing on expanding its original equipment manufacturing (OEM) services, which have shown promising growth, including a major order from a new customer, Qnet Limited. As of September 30, 2025, the company had cash and equivalents of $28,741, a significant increase from $1,371 at the end of 2024.

The company’s balance sheet reflects total assets of $184,534, down from $281,024 at the end of 2024, primarily due to a decrease in prepaid expenses and other receivables. Current liabilities increased to $3,230,021 from $2,802,700, largely driven by a rise in customer deposits. The accumulated deficit as of September 30, 2025, stood at $10,582,160, raising concerns about the company's ability to continue as a going concern. Management has indicated plans to strengthen its sales force and explore additional financing options, including potential public or private offerings, to support future operations.

Looking ahead, Bio Essence aims to enhance its revenue generation capabilities through strategic marketing and sales initiatives while continuing to seek opportunities for growth in the OEM sector. However, the company acknowledges the challenges posed by its current financial position and the need for additional funding to sustain operations in the coming year.